In one paragraphArticle in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
25 authors.
Rachel S KellyChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.ORCID 0000-0003-3023-1822 Stacey N ReinkeSchool of Science, Edith Cowan University, 270 Joondalup Drive, Joondalup WA, 6027, Australia.ORCID 0000-0002-0758-0330 Georgia LorentzenDivision of Systems Medicine, Department of Metabolism, Digestion, & Reproduction, Imperial College London, London, United Kingdom.ORCID 0009-0003-4244-7310 Anastasia Chrysovalantou ChatziioannouNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-1973-7542 Ruey Leng LooCentre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA 6150 Australia.ORCID 0000-0001-5307-5709 Lorraine BrennanUCD School of Agriculture and Food Science, Institute of Food and Health, University College Dublin, Dublin 4, Ireland.ORCID 0000-0002-7711-7499 Elena ColicinoDepartment of Environmental Medicine, Division of Biostatistics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-1875-8448 Robert van VorstenboschInstitute of Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-1953-0207 Amir Hossein Alizadeh BahmaniDepartment of Vascular Medicine, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-5249-6261 Antonio ChecaUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8113-0653 Salman SiddiquiThe National Phenome Centre, Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Institute of Reproductive and Developmental Biology, Hammersmith Hospital Campus, London W12 0NN, United Kingdom.ORCID 0000-0001-8433-4275 Anisha WijeyesekeraFood Microbial Sciences Unit, Department of Food and Nutritional Sciences, University of Reading, Reading, RG6 6DZ, United Kingdom.ORCID 0000-0001-6151-5065 David BroadhurstSchool of Science, Edith Cowan University, 270 Joondalup Drive, Joondalup WA, 6027, Australia.ORCID 0000-0003-0775-9581 Steven C MooreMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID 0000-0002-8169-1661 Timothy EbbelsSection of Bioinformatics, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Campus, London, W12 0NN, UK.ORCID 0000-0002-3372-8423 Matthias EggerCenter for Reproducible Science and Research Synthesis, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7462-5132 Royston GoodacreCentre for Metabolomics Research, Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, BioSciences Building, Crown St., Liverpool, UK, L69 7ZB.ORCID 0000-0003-2230-645X Julian LittleSchool of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON K2P 2C9, Canada.ORCID 0000-0001-5026-5531 Craig E WheelockUnit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm SE-171 77, Sweden.ORCID 0000-0002-8113-0653 Jessica Lasky-SuChanning Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.ORCID 0000-0001-6236-4705 Funding
Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015AOT2HL161841 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI FOULKES, ANDREA S, KARLSON, ELIZABETH W · 2021 to 2024
$182.2MProteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0MOmic Determinants of Longitudinal Lung Function in AsthmaR01HL155742 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LASKY-SU, JESSICA A, MCGEACHIE, MICHAEL JOHN · 2021 to 2025
$3.9MEarly-life metal exposures, mitochondrial heteroplasmy, and child antibody response to vaccinationR01ES034521 · NIEHS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elena Colicino, Todd Jusko · 2022 to 2026
$3.0MBetter utilization of omics data to inform precision medicine for asthma throughout the life courseR01HL169300 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI JESSICA A LASKY-SU · 2024 to 2026
$2.3MAir Particulate Pollution and Stress: Effects and Mechanisms for Long-term Maternal Obesity RisksR01ES032242 · NIEHS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLICINO, ELENA, WU, HAOTIAN · 2020 to 2024
$2.2MIdentifying Subtypes of COPD Using Metabolomic and Genomic ApproachesR01HL168199 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO · 2024 to 2026
$2.1MIdentifying causal mechanisms of metabolites in family-based association studies of childhood asthmaR01HL176792 · NHLBI · HARVARD PILGRIM HEALTH CARE, INC. · PI LUTZ, SHARON MARIE · 2025 to 2025
$1.5MIntegrative Metabolomics of Sarcoidosis Diagnosis and ProgressionR01HL173239 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Shu-Yi Liao · 2025 to 2026
$1.5MMultiple long-term environmental exposures and incidence of asthmaR01ES036205 · NIEHS · BRIGHAM AND WOMEN'S HOSPITAL · PI JAIME ELIZABETH HART · 2025 to 2026
$1.4MCommon and distinct metabolic pathways of pulmonary sarcoidosis phenotypes and endotypesR21HL175174 · NHLBI · NATIONAL JEWISH HEALTH · PI LIAO, SHU-YI · 2025 to 2025
$249kNHLBI NIH HHS OT2 HL161841NHLBI NIH HHS R01 HL155742NHLBI NIH HHS R01 HL168199NHLBI NIH HHS R01 HL169300NHLBI NIH HHS R01 HL173239NHLBI NIH HHS R01 HL176792NHLBI NIH HHS R21 HL175174NIAID NIH HHS U19 AI168643NIEHS NIH HHS R01 ES032242NIEHS NIH HHS R01 ES034521NIEHS NIH HHS R01 ES036205
6 · The paper itselfAbstract
Metabolomic epidemiology has expanded rapidly, but publications often lack sufficient detail for readers to assess study design, analytical methods, sources of bias, and the robustness and reproducibility of findings. Existing reporting recommendations in epidemiology and metabolomics do not fully address the specific challenges that arise when these fields are combined. To improve the completeness and transparency of reporting, we developed the Strengthening the Reporting of Metabolomic Epidemiology (STROBE-MetEpi) statement, an extension of the original STROBE guidance for observational research. The STROBE-MetEpi checklist includes 31 items and subitems covering the Title, Abstract, Introduction, Methods, Results, Discussion, and Other Information sections of metabolomic epidemiology studies. This explanation and elaboration document is intended to complement the STROBE-MetEpi statement by explaining the rationale for each checklist item and providing published examples of transparent reporting. It applies to studies using metabolomic profiling to explore human health, but not to randomized trials, methodological studies, reviews, or multi-omics studies. As with previous STROBE explanation and elaboration documents, its purpose is to improve how studies are reported, not to prescribe how they should be conducted. The STROBE-MetEpi statement and this accompanying document should support authors, reviewers, editors, and readers in improving the reporting, appraisal, interpretation, and reproducibility of metabolomic epidemiology research.
Indexed as
Metabolomic EpidemiologyReporting guidelinesSTROBESTROBE-MetEpi
Identifiers
PMID42396500
PMCPMC13321282
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390